Compounded Ozempic-like products could face a TGA ban
Eucalyptus Clinical Director Dr. Matt Vickers discusses the TGA proposal to disallow the compounding of semaglutide, raising concerns for thousands of patients.
Hear more highlights from Drive with Chris O’Keefe below: